CN109142730A - A kind of anti-PSIP1 autoantibody of lung cancer marker and its application - Google Patents
A kind of anti-PSIP1 autoantibody of lung cancer marker and its application Download PDFInfo
- Publication number
- CN109142730A CN109142730A CN201810611747.9A CN201810611747A CN109142730A CN 109142730 A CN109142730 A CN 109142730A CN 201810611747 A CN201810611747 A CN 201810611747A CN 109142730 A CN109142730 A CN 109142730A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- psip1
- autoantibody
- detection
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Abstract
The invention belongs to technical field of biomedical detection, and in particular to a kind of anti-PSIP1 autoantibody of lung cancer marker and its application, the invention discloses a kind of lung cancer marker, the lung cancer marker is anti-PSIP1 autoantibody.The present invention also provides above-mentioned lung cancer marker in preparation for the application in lung cancer detection kit.The present invention provide it is a kind of it is easy to operate, at low cost, accuracy is high, the serum biomarkers for being applied to clinical lung cancer detection of hurtless measure.The research of the invention finds that carrying out the detection of the anti-PSIP1 autoantibody of serum using ELISA method, accurately patients with lung cancer and normal person and benign consumptive can be distinguished to come, and can be used for the detection of pulmonary metastasis.The marker and the marker that there is provided this convenient, fast, effective detection patients with lung cancer in this context are used for the kit of lung cancer detection in preparation, can be used for clinical lung cancer early diagnosis.
Description
Technical field
The invention belongs to technical field of biomedical detection, and in particular to a kind of anti-PSIP1 autoantibody of lung cancer marker
And its application.
Background technique
Lung cancer is the malignant tumour of China and global incidence and the death rate first.The complicated clinical manifestation of lung cancer is more
Sample, early stage of lung cancer performance concealment and diversification, Clinical symptoms and sign are unobvious, be showed only as coughing, cough up phlegm, pectoralgia, fever,
The nonspecific symptoms such as physically-draining cause most of patients with lung cancer to be in advanced stage when finding.There is clinical data to show, has
Advanced lung cancer has been in when nearly 60% patient assessment.5 years survival rates of advanced lung cancer are only 16% or so, and lung cancer early stage (I
Phase) five year survival rate can be up to 70%.It can be seen that the early detection of lung cancer, early diagnosis are to reduce lung cancer morbidity rate and death
The key link of rate.
Clinically there are many detection means for being used for lung cancer at present, mainly include noninvasive test (CT, x-ray rabat etc.) and one
It is a little invasive to check (branchofiberoscope, exfoliative cytology inspection, through CT localised puncture biopsy etc.).X-ray rabat easily and fast,
The advantages such as noninvasive, it is significant to pulmonary cancer diagnosis, but it is a lack of compliance and popularization, it can only be as the finger of auxiliary diagnosis
Mark.Cytology and Histopathological method are the goldstandards for making a definite diagnosis lung cancer, but difficulty of drawing materials is big, is not used to large-scale people
Group's screening.In recent years, serum biological markers are easy to operate due to traumatic small, and screening range is wide, and detection efficiency height etc. is excellent
It puts and attracts attention.Serum biological markers clinically have carbohydrate antigen (CA125, CA199), cytokeratin at present
19 fragment antigens (CYFRA21-1), carcinomebryonic antigen (CEA) etc., but not yet find that a kind of sensitivity and specificity are very high
Tumor markers.
The generation of tumour can be attributed to a series of exception of tumor-related gene structures or function, tumour antigen
(tumor-associated antigens, TAAs) is exactly some upper abnormal in matter or amount expressed by these aberrant genes
Protein or polypeptide, generate antibody be known as anti-TAA autoantibody.Since to be mainly distributed on tumour thin for tumour antigen
In intracellular, film surface or serum, body specificity or nonspecific humoral immune response and cell are activated to some extent
Immune response.Anti- TAAs autoantibody is not present in normal person and non-Serum of Cancer Patients or titre is very low, patients serum
The raising of middle autoantibody is often earlier than the appearance of tumor manifestations, and it can continually and steadily exist in serum, and
Other markers, including TAA itself, after it is discharged by tumour cell by fast degradation or its enter blood circulation
It can be removed by body in very short time afterwards.Therefore the autoantibody for detecting anti-TAAs can be used as infantile tumour diagnosis
Blood serum designated object.
PSIP1, i.e. PC4 and SFRS1 interaction protein also known as DFS70, P75/LEDGF.DFS70 autoantigen is initial
It is to be found in research of the 1990s to interstitial cystitis and chronic fatigue syndrome, and P75/ LEDGF
Autoantigen derives from the lens epithelial cells in cataract patient earliest.In recent years, it is anti-as a kind of multi-function emergency
Albumen is answered, has extensive relationship with cancer, autoimmunity, eye disease and AIDS etc..There are many studies have shown that P75/LEDGF
Expression in prostate cancer and other cancers is all up-regulation, and overexpression and tumour of this albumen in cancer cell are invaded
Attacking property, migration, clonogenic, angiogenesis and tumour growth etc. are related.
Oncomine database (http://www.oncomine.org) is a database based on genetic chip and whole
Data mining platform is closed, tumor transcriptional group data are provided.Oncomine can analyze some target gene in tumor tissues and normal
The differential expression of tissue, and some important clinical information such as gene and tumor size, transfer, life span can be obtained.
Whether PSIP1 gene combination Oncomine database is carried out the excavation of depth by the present invention, and may be used to anti-PSIP1 autoantibody
Serology to have carried out large sample size as diagnosing specific index is verified.
In conclusion improve survival rate to finally realize the death rate for reducing lung cancer, there is an urgent need in the art to screening and
It identifies more sensitive, specific serum autoantibody markers, and develops inspection easy to operate, at low cost, applied widely
Survey the kit of lung cancer autoantibody.
Summary of the invention
It is an object of the invention to overcome the problems, such as that the existing tumor markers of lung cancer are undesirable, it is desirable to provide anti-PSIP1 is certainly
The new application of body antibody, in sensitivity, specificity and the accuracy for improving pulmonary metastasis diagnosis.High using a species specificity,
Good, the easy to detect kit for pulmonary cancer diagnosis of the strong diagnosis marker preparation stability of susceptibility.The present invention specifically mentions
For a kind of Sera of Lung Cancer diagnosis marker, and in particular to a kind of anti-PSIP1(PC4 And that can distinguish lung cancer and normal person
SFRS1- interacting Protein 1) autoantibody.
To achieve the above object, the invention adopts the following technical scheme:
In a first aspect, the lung cancer marker is anti-PSIP1 autoantibody the present invention provides a kind of marker for lung cancer.
Second aspect, the present invention provides the anti-PSIP1 autoantibodies described in first aspect to be used for Sera of Lung Cancer in preparation
Learn the application in the reagent or kit of detection.
Preferably, the kit is the detection architecture based on enzyme-linked immunosorbent assay (ELISA).
Preferably, the reagent or kit contain the PSIP1 recombination purifying protein for detecting anti-PSIP1 autoantibody.
Preferably, the kit also contains ELISA coating buffer (20 ×), HRP-Rec-A secondary antibody, Block buffer
(BSA), ELISA universal antibody dilution, ELISA-ABTS colour reagent, PBST(polysorbas20-phosphate buffer), terminate
Liquid.
Compared with prior art, the invention has the benefit that
The present invention provide it is a kind of it is easy to operate, at low cost, accuracy is high, the serum for being applied to clinical lung cancer detection of hurtless measure
Biomarker.The research of the invention finds that the detection of the anti-PSIP1 autoantibody of serum is carried out using ELISA method, it can be calibrated
Really patients with lung cancer and normal person and tuberculosis patients with chronic diseases are distinguished to come, and can be used for the inspection of pulmonary metastasis
It surveys.The marker and the marker for providing this convenient, fast, effective detection patients with lung cancer in this context are being prepared for lung
The kit of cancer detection can be used for clinical lung cancer early diagnosis.
Detailed description of the invention
Fig. 1 is distribution and ROC curve of the anti-PSIP1 autoantibody in lung cancer group and Normal group point in test group
Analysis, (wherein, Figure 1A is the distribution of autoantibody, and Figure 1B is ROC curve analysis)；
Fig. 2 is the distribution that anti-PSIP1 autoantibody is horizontal in lung cancer group, Normal group and benign tuberculosis group in validation group；
Fig. 3 is anti-PSIP1 autoantibody in ROC curve analysis validation group to the detection efficiency (LC: lung cancer group of lung cancer；B: benign
Tuberculosis group；N: Normal group)；
In lung cancer, whether there is or not the detection efficiency (N: normal in transfer for anti-PSIP1 autoantibody in ROC curve analysis validation group by Fig. 4
Control group).
Specific embodiment
The present invention analyzes PSIP1 mRNA expression using three separate queues research of Oncomine database, answers
With anti-PSIP1 autoantibody in ELISA method detection Serum of Patients with Lung Cancer.
1) using three separate queues research of Oncomine database, (including 375 non-small cell lung cancers and 134 are just
Often tissue) it is excavated, the expression of PSIP1 mRNA in lung cancer and normal tissue is analyzed, finds the lung cancer group studied at three
In be low expression.
2) right using ELISA detection method in order to examine anti-PSIP1 autoantibody that can be used as pulmonary cancer diagnosis marker
184 Serum of Patients with Lung Cancer and 184 normal human serums carry out the detection of anti-PSIP1 autoantibody, step packet
It includes: the PSIP1 recombination purifying protein of purchase being diluted to 0.5 ug/ml with antigen coat buffer, is coated with 96 orifice plates, it is general anti-
Body dilution dilutes serum sample 1:100, the recombinant protein A (HRP- after antigenic action, with horseradish peroxidase-labeled
Rec-Protein A) antibody response, it ultimately joins ABTS substrate solution and develops the color, read under microplate reader (405nm absorbance)
OD value, to react the level of anti-PSIP1 autoantibody in serum.The results show that anti-PSIP1 autoantibody is in patients with lung cancer blood
Expression in clear is higher than normal human serum, has statistical significance (P < 0.001, as shown in Figure 1).In order to further verify
Whether anti-PSIP1 autoantibody can be used for the screening indexes of lung cancer, good in 446 lung cancer, 446 normal controls and 119
Property tuberculosis in carry out ELISA detection, as the result is shown anti-PSIP1 autoantibody in Serum of Patients with Lung Cancer expression difference it is big
In Normal group and benign tuberculosis group (P < 0.001, as shown in Figure 2).
3) in order to detect anti-PSIP1 autoantibody for the distinguishing ability of patients with lung cancer, the present invention by lung cancer group with
Normal group, lung cancer group and benign tuberculosis group and lung cancer group and non-lung cancer group (Normal group+benign tuberculosis group) carry out
ROC curve analysis, the results show that lung cancer group and the area under the curve of Normal group are 0.673 (95%CI:0.641-
0.704), the area under the curve of lung cancer group and benign tuberculosis group is 0.700 (95%CI:0.660-0.737), lung cancer group and non-lung
The area under the curve of cancer group (benign tuberculosis group+Normal group) is 0.678(95%CI:0.649-0.707) (as shown in Figure 3).
Anti- PSIP1 autoantibody can be very good to distinguish lung cancer and non-lung cancer patient.
It 4) is the application value for further appreciating that anti-PSIP1 autoantibody in pulmonary metastasis diagnosis, the present invention couple
Anti- PSIP1 autoantibody have at 217 transfer lung cancer and 64 without transfer Serum of Patients with Lung Cancer in carry out positive rate analysis, knot
Fruit show anti-PSIP1 autoantibody have transfer lung cancer in positive rate be 30.0%, without transfer lung cancer in positive rate be
17.2%, there is the positive rate in transfer lung cancer to be apparently higher than non-metastatic lung cancer (P < 0.05).With 446 Normal groups into
Row ROC analysis, there is the AUC value 0.666(95%CI:0.629-0.702 of transfer lung cancer and Normal group as the result is shown), nothing turns
The AUC value 0.567(95%CI:0.522-0.610 of shifting property lung cancer and Normal group) (as shown in Figure 4), the index is for transfer
Property lung cancer diagnostic value be higher than non-metastatic lung cancer.The result shows that anti-PSIP1 autoantibody provided by the invention can be used as
Predict the diagnosis marker of pulmonary metastasis.
Below by specific embodiment, the invention will be further described.
Embodiment 1
1, serum specimen is collected
The present invention is included in research object 1379 altogether, is divided into test group and validation group, test group is for screening to pulmonary cancer diagnosis valence
It is worth higher index, validation group carries out the verifying of high-volume serology to these indexs.184 patients with lung cancer that test group is included in
Patients with lung cancer of the serum from the first affiliated hospital of 2016-2017 Zhengzhou University.446 patients with lung cancer blood that validation group is included in
It went to a doctor from -2014 years 2013 in the patients with lung cancer of the first affiliated hospital of Zhengzhou University clearly.All cases pass through tissue
Pathology are made a definite diagnosis, without any operation and chemicotherapy.446 normal controls of 184 normal controls of test group and validation group are equal
From the first affiliated hospital of Zhengzhou University physical examination of healthy population, matched according to age-sex with case, and be not suffering from swollen
Tumor related disease and respiratory disease.119 benign tuberculosis serum are from the attached doctor of 2016-2017 Zhengzhou University first
Institute, including chronic obstructive emphysema patient and chronic pneumonia patient.All research objects exclude autoimmune disease and
The disease of the influence protein expression such as acute and chronic infection.
After all research objects blood sampling 5ml, static 30min, take supernatant to Eppendorf after 3000rpm centrifugation 5min
Keep sample in pipe, is included in sample storehouse after giving number respectively, -20 DEG C of refrigerators, point of long-term preservation are stored in after short-period used packing
It freezes spare in -80 DEG C of refrigerators after dress, avoids multigelation.
2, Oncomine database carries out mRNA expression analysis to PSIP1
It is analyzed using expression of the Oncomine database to PSIP1 mRNA.3 different numbers are selected in the present invention
According to collection Dataset(45 cancerous lung tissues of Hou Lung and 65 normal tissues), Dataset(226 lungs of Okayama Lung
Cancerous tissue and 20 normal tissues), Dataset(58 cancerous lung tissues of Landi Lung and 49 normal tissues).Compare
Differential expression of the PSIP1 in non-small cell lung cancer and normal tissue.Search condition 1, Gene are set in Oncomine database:
PSIP1；2, Analysis Type:Cancer vs.Normal Analysis；3, Cancer Type:Non-small Cell
Lung Cancer；4, Sample Type:Clinical Specimen；5, Data Type:mRNA.Critical value setting condition is
P-value (0.05/ gene number) after correction: Hou Lung Dataset≤2.55E-6；Okayama Lung≤2.55E-6；
Landi Lung≤3.96E-6.Result of study show PSIP1 three research in show low expression, be as a result respectively P=
8.64E-7 FC=- 1.588；P=4.06E-15, FC=- 1.662；P=1.15E-11, FC=- 1.763.
3. the serum expression of the anti-PSIP1 autoantibody of ELISA method detection
Reagent needed for 3.1
It is raw that universal antibody dilution, coating buffer (20x), Block buffer, ABTS- colour reagent box are purchased from the raw work in Shanghai
Object Engineering Co., Ltd.
Universal antibody dilution: ingredient is BSA(bovine serum albumin(BSA)) and PBS buffer solution.
Coating buffer (20x): ingredient is carbonate buffer solution, with deionized water by 1:20 dilution when use.
10 × ELISA PBST washing lotion (1L): NaCl 81.8g, Na are weighed2HPO4•12H2O 28.8g, NaH2PO4•2H2O
3.1g, Tween20 5ml, merthiolate 0.1g, add deionized water to 1L.
1 × ELISA PBST washing lotion (1L): 10 × ELISA PBST washing lotion 100ml is taken, adds deionized water to 1L.
3.2 anti-PSIP1 autoantibody detection methods
(1) envelope antigen albumen: the PSIP1 bought from biotech firm recombinates purifying protein, dilute with antigen protein coating buffer
It releases to 0.5ug/ml final concentration, is coated in 96 orifice plates, sample-adding 50The hole l/, preservative film closing prevent from volatilizing, and are placed in 4 DEG C of refrigerator packets
It is stayed overnight.
(2) it closes: discarding coating buffer in hole, every hole is added 100 in 96 hole elisa PlatesThe closing containing 2%BSA of l is slow
Fliud flushing is placed in 37 DEG C of thermostat water bath closing 2h, sufficiently throws away Block buffer, ELISA Plate is placed in automatic washer, press
According to set program (200L washing buffer/hole, is repeated 3 times 20 s/ time) washing, it pats dry.
(3) one antiserums are incubated for: test serum are diluted using the PBST serum thin liquid containing 1%BSA, it is diluted
Ratio is 1:100, and 96 hole elisa Plates after closing are separately added into 50Test serum after l dilution and the yin-yang after dilution
Serum dilution is only added in control serum, blank control wells, is placed in 37 DEG C of water-baths and is incubated for 1h, sufficiently throws away liquid in hole, set
It is washed in board-washing machine, is patted dry after washing.
(4) secondary antibody is incubated for: regarding the recombinant protein A (HRP-rec-Protein A) of horseradish peroxidase-labeled as two
It is anti-, after mixing well containing 1%BSA according to 1:3000 dilution proportion, it is separately added into 96 hole elisa Plates, every hole 50L is placed in
37 DEG C of water-baths are incubated for 1h, after discard liquid in hole, PBST washing lotion board-washing 3 times pats dry.
(5) develop the color: each reacting hole is added 50L mixed reaction solution is placed in 37 DEG C of water-baths and is protected from light colour developing 30min to green
Color product occurs.
(6) reaction: the every hole 25ul of terminate liquid is terminated, then measures its absorbance value OD using microplate reader405nmPlace, with blank
Each hole OD value is surveyed after control wells zeroing.
4. statistical analysis technique
The present invention examines the difference for autoantibody contents level between analyzing two groups of test group using Mann-Whitney U.It adopts
Compare the difference of three groups of autoantibody contents levels in validation group with non-parametric test (Kruskal-Wallis).With specificity height
When 90%, sensitivity highest is determined as the positive as cutoff value, higher than this value, is determined as feminine gender lower than this value.Solely using two
Vertical sample Chi-square Test is to whether there is or not the comparisons that transfer carries out autoantibodies rate.ROC is carried out using MedCalc12.0 software
Tracing analysis judges antibody to the distinguishing ability of lung cancer according to area under the curve (AUC).All statistical analysis use SPSS20.0
Software carries out, and P < 0.05 is Statistic analysis standard.
5. clinically detecting application of the anti-PSIP1 autoantibody in lung cancer detection
(1) diagnostic value of the anti-PSIP1 autoantibody in lung cancer
The present invention carries out 184 Serum of Patients with Lung Cancer in test group and 184 normal human serums with ELISA detection method anti-
The detection of PSIP1 autoantibody, the results show that the level of the anti-PSIP1 autoantibody of lung cancer group is significantly higher than normal control
Group (P < 0.001, as shown in Figure 1A).By the comparison to autoantibodies rate, lung cancer group positive rate (32.0%) is obvious high
In Normal group (9.8%), two group differences are statistically significant (P < 0.001).Anti- PSIP1 autoantibody is in lung cancer pair
It is 0.668 (0.617-0.716) (as shown in Figure 1B) in the AUC of normal person and 95% credibility interval, sensitivity and specificity are distinguished
For 32.0% and 90.2%.
(2) identification energy of the anti-PSIP1 autoantibody to lung cancer group and non-lung cancer group (Normal group+benign tuberculosis group)
Power
Anti- PSIP1 autoantibody content is higher than Normal group and benign tuberculosis group in lung cancer group in validation group, poor between group
Different statistically significant (P < 0.001) (as shown in Figure 2).Lung cancer group and the area under the curve of Normal group are 0.673 (95%
CI:0.641-0.704), the area under the curve of lung cancer group and benign tuberculosis group is 0.700 (95%CI:0.660-0.737), lung
Cancer group and the area under the curve of non-lung cancer group (Normal group+benign tuberculosis group) are 0.678(95%CI:0.649-0.707)
(as shown in Figure 3).Invention prompt, anti-PSIP1 autoantibody can well by lung cancer group and non-lung cancer group (Normal group+
Benign tuberculosis group) it is distinguished.
(3) anti-PSIP1 autoantibody is to the diagnostic value for having transfer lung cancer
By to anti-all clinical datas of PSIP1 autoantibody (age, gender, by stages, histological type, transfer case, tumour
Family history smokes, drinks) positive rate analyzed, as the result is shown anti-PSIP1 autoantibody having transfer lung cancer in sun
Property rate (30.0%) be apparently higher than without transfer lung cancer in positive rate (17.2%), two group differences it is statistically significant (P <
0.05).Other are as the result is shown in the autoantibodies rate no significant difference of different Clinical symptoms.Anti- PSIP1 itself
Antibody whether there is or not the ROC in transfer the results show that having area under the curve AUC and 95% credibility interval of the transfer lung cancer to normal person
It is 0.666(95%CI:0.629-0.702), no transfer lung cancer is 0.567 to the area under the curve AUC of normal person and credibility interval
(95%CI:0.522-0.610) (as shown in Figure 4).By the AUC between two groups of Medcalc comparison, as the result is shown between two groups
Difference is statistically significant (P < 0.05).
Result prompt of the present invention, anti-PSIP1 autoantibody can be used as the biomarker of prediction lung cancer development, and its
Application in reagent or kit of the preparation for Sera of Lung Cancer detection.
The foregoing is only a preferred embodiment of the present invention, the scope of protection of the present invention is not limited to this, it is any ripe
Know those skilled in the art within the technical scope of the present disclosure, the letter for the technical solution that can be become apparent to
Altered or equivalence replacement are fallen within the protection scope of the present invention.
Claims (5)
1. a kind of marker for lung cancer, which is characterized in that the lung cancer marker is anti-PSIP1 autoantibody.
2. a kind of anti-PSIP1 autoantibody of lung cancer marker as described in claim 1 is detected in preparation for Sera of Lung Cancer
Reagent or kit in application.
3. detecting the kit of lung cancer according to claim 2, which is characterized in that the kit is inhaled based on enzyme linked immunological
The detection architecture of adhesion test.
4. detecting the kit of lung cancer according to claim 3, which is characterized in that the kit contains the anti-PSIP1 of detection
The PSIP1 of autoantibody recombinates purifying protein.
5. detecting the kit of lung cancer according to claim 3, which is characterized in that the kit also contains ELISA coating
Buffer, HRP-Rec-A secondary antibody, Block buffer, ELISA universal antibody dilution, ELISA-ABTS colour reagent, PBST,
Terminate liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810611747.9A CN109142730B (en) | 2018-06-14 | 2018-06-14 | Lung cancer marker anti-PSIP 1 autoantibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810611747.9A CN109142730B (en) | 2018-06-14 | 2018-06-14 | Lung cancer marker anti-PSIP 1 autoantibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109142730A true CN109142730A (en) | 2019-01-04 |
| CN109142730B CN109142730B (en) | 2021-04-23 |
Family
ID=64802009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810611747.9A Active CN109142730B (en) | 2018-06-14 | 2018-06-14 | Lung cancer marker anti-PSIP 1 autoantibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109142730B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110412274A (en) * | 2019-06-26 | 2019-11-05 | 四川大学华西医院 | C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
| CN110456063A (en) * | 2019-07-31 | 2019-11-15 | 四川大学华西医院 | TPM2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080254481A1 (en) * | 2006-11-13 | 2008-10-16 | Invitrogen Corporation | Methods and kits for detecting prostate cancer biomarkers |
| CN102326080A (en) * | 2009-02-20 | 2012-01-18 | 加利福尼亚大学董事会 | A+ biomarker assays |
| US20130310266A1 (en) * | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| WO2014195730A2 (en) * | 2013-06-07 | 2014-12-11 | Sense Proteomic Limited | Auto-antigen biomarkers for lupus |
| CA2982998A1 (en) * | 2015-04-17 | 2016-10-20 | The Regents Of The University Of California | Methods for detecting agglutination and compositions for use in practicing the same |
-
2018
- 2018-06-14 CN CN201810611747.9A patent/CN109142730B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080254481A1 (en) * | 2006-11-13 | 2008-10-16 | Invitrogen Corporation | Methods and kits for detecting prostate cancer biomarkers |
| CN102326080A (en) * | 2009-02-20 | 2012-01-18 | 加利福尼亚大学董事会 | A+ biomarker assays |
| US20130310266A1 (en) * | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| WO2014195730A2 (en) * | 2013-06-07 | 2014-12-11 | Sense Proteomic Limited | Auto-antigen biomarkers for lupus |
| CA2982998A1 (en) * | 2015-04-17 | 2016-10-20 | The Regents Of The University Of California | Methods for detecting agglutination and compositions for use in practicing the same |
| CN107614699A (en) * | 2015-04-17 | 2018-01-19 | 加利福尼亚大学董事会 | For detecting the method for aggegation and composition for putting into practice this method |
Non-Patent Citations (3)
| Title |
|---|
| TRACY D ET AL.: "Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis", 《THE PROSTATE》 * |
| ZAENKER P ET AL.: "Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review", 《CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION》 * |
| 王健 等: "自身抗体诊断应用研究进展", 《检验医学与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110412274A (en) * | 2019-06-26 | 2019-11-05 | 四川大学华西医院 | C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
| CN110456063A (en) * | 2019-07-31 | 2019-11-15 | 四川大学华西医院 | TPM2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109142730B (en) | 2021-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mossad et al. | Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma | |
| US9778259B2 (en) | Method for diagnosing invasive Candida infections | |
| CN110187113A (en) | A kind of autoantibody joint-detection ELISA kit for esophageal squamous cell carcinoma early screening | |
| Hernandez-Gonzalez et al. | Evaluation of the recombinant antigens B2t and 2B2t, compared with hydatid fluid, in IgG-ELISA and immunostrips for the diagnosis and follow up of CE patients | |
| Zhang et al. | Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma | |
| CN108646032A (en) | Purposes of the TOP2A autoantibodies as pulmonary cancer diagnosis marker | |
| CN109061164A (en) | For the composite marker object of Diagnosis of Non-Small Cell Lung and its application | |
| CN110187109A (en) | A kind of autoantibody joint-detection ELISA kit for Grades of Gastric Cardia Adenocarcinoma early screening | |
| CN102687011A (en) | Cancer biomarker and the use thereof | |
| CN112345755A (en) | Biomarker of breast cancer and application thereof | |
| CN113215254B (en) | Immune-clinical characteristic combined prediction model for evaluating lung adenocarcinoma prognosis | |
| CN109342727A (en) | Esophageal squamous cell carcinoma autoantibody molecular marker model and its application | |
| CN109116024A (en) | A kind of anti-ACTR3 autoantibody of lung cancer marker and its application | |
| US20120295288A1 (en) | Serological marker for detecting pancreatic cancer and a method for using the serological marker | |
| CN109142729B (en) | Lung cancer marker anti-HMGB 3 autoantibody and application thereof | |
| CN111562378A (en) | Construction method of ELISA detection kit, kit and application | |
| CN109142730A (en) | A kind of anti-PSIP1 autoantibody of lung cancer marker and its application | |
| CN107255711A (en) | Osteopontin is used for the purposes for preparing or screening acute-on-chronic liver failure diagnostic reagent | |
| Xu et al. | Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer | |
| Leman et al. | Retracted: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA‐2 | |
| Wang et al. | Latent transforming growth factor β binding protein 2 (LTBP2) as a novel biomarker for the diagnosis and prognosis of pancreatic carcinoma | |
| US8951738B2 (en) | CYBP as a marker for lung cancer | |
| Zhang et al. | Screening and surveillance of multiple solid tumours using plasma placental-like chondroitin sulfate A (pl-CSA) | |
| CN108369233A (en) | The method and associated uses of the recurrence of adenocarcinoma of lung are detected based on marker people epididymal proteins 4 (HE4) | |
| CN113030457B (en) | Use of PCNA autoantibodies in cancer prediction, diagnosis and prognosis evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |